Buyers eye Relypsa and its hyperkalemia drug

ZS Pharma

While pharma M&A action has slowed, it is not dead. After AstraZeneca ($AZN) last year agreed to pay $2.7 billion for ZS Pharma ($ZSPH) it stoked interest in new treatments for the blood disorder hyperkalemia, and Relypsa ($RLYP) has one already approved, Veltassa. That, Reuters says, has drawn buyout interest, leading the Redwood City, CA-based biotech to hire an investment bank to check out its offers. Relypsa isn't commenting but the news service says several companies that had bid on ZS, including Actelion, are eyeing Relypsa. More from FierceBiotech


Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.